---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Expected outcomes of therapy"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Expected outcomes of therapy. Topics: Darovasertib plus crizotinib: response, duration of response, and overall survival trend in the OptimUM-02 topline results; Darovasertib plus crizotinib: progressive disease as best response and discussant assessment against checkpoint inhibitor outcomes; Historical response, progression-free survival, and overall survival benchmarks cited by the sponsor; Historical 5-year survival in metastatic uveal melanoma; 2 further topics. 6 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/expected-outcomes-of-therapy"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Expected outcomes of therapy

<a id="heading-2.2.2.7"></a>

## 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

### Darovasertib plus crizotinib: response, duration of response, and overall survival trend in the OptimUM-02 topline results

> “The overall response rate (ORR) by BICR in the darovasertib combination and ICT arm was 37.1% and 5.8% (p-value: <0.0001), respectively.”
> “There were 5 complete responses by BICR observed in the darovasertib combination arm, and no complete responses observed in the ICT arm.”
> “The median duration of response (DOR) in the darovasertib combination arm was 6.8 months.”
> “However, in the OptimUM-02 study, there is an early trend in improvement in OS with the darovasertib combination arm versus the ICT arm.”

Source: [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma)

<a id="topic-2.2.2.7-2"></a>

### Darovasertib plus crizotinib: progressive disease as best response and discussant assessment against checkpoint inhibitor outcomes

> “Progressive disease as best response occurred in 6.2% of patients who received darovasertib plus crizotinib vs 28.2% of those assigned to investigator’s choice.”
> “In a disease where checkpoint inhibitors typically achieve response rates in the low teens and short progression-free survivals, these results clearly stand out,”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

<a id="topic-2.2.2.7-3"></a>

### Historical response, progression-free survival, and overall survival benchmarks cited by the sponsor

> “Based on data from large meta-analyses published by Khoja and Rantala it has been shown that mUM has an especially poor prognosis, with a reported median PFS of 2.8 months and median OS of ~12 months in the treatment-naïve setting.”
> “In the 2L setting, median PFS remains at ~2-3 months but median OS drops to ~8 months with a 1-year OS rate of ~37%.”
> “As shown in the table above the data from OptimUM-01 compares favorably to these historical PFS and OS benchmarks, as well as to historical ORR which is typically ~5%.”

Source: [IDEAYA Biosciences press release, ESMO 2026 data (2026)](https://media.ideayabio.com/2026-10-19-IDEAYA-Biosciences-and-Servier-Announce-Data-From-Three-Clinical-Trials-at-ESMO-2026-Supporting-the-Potential-of-Darovasertib-to-Become-a-Foundational-New-Therapy-for-Patients-Across-the-Treatment-Journey-of-Uveal-Melanoma)

> “Historical mOS of 10-12 months”
> “Median PFS and OS compared favorably to historical meta-analyses in first-line mUM”

Source: [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf)

<a id="topic-2.2.2.7-4"></a>

### Historical 5-year survival in metastatic uveal melanoma

> “Metastatic uveal melanoma (mUM) carries a poor prognosis, with only an estimated 2% of patients historically surviving 5 years.”

Source: [Piperno-Neumann et al. (2026b)](https://www.annalsofoncology.org/article/S0923-7534%2826%2900879-3/fulltext)

<a id="topic-2.2.2.7-5"></a>

### Tebentafusp: median overall survival in the primary analysis and 5-year survival in HLA-A∗02:01-positive disease

> “The median OS was 21.7 months with tebentafusp versus 16.9 months with investigator’s choice.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

> “Five-year overall survival (OS) data from the pivotal phase 3 IMCgp100-202 trial (NCT03070392), presented at the 2026 AACR Annual Meeting, demonstrated an OS rate of 16% with tebentafusp (n = 252) vs 8% with investigator's choice of therapy (n = 126) in patients with previously untreated HLA-A*02:01–positive metastatic uveal melanoma.”

Source: [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape)

<a id="topic-2.2.2.7-6"></a>

### Expert expectation of real-world overall survival with tebentafusp-based treatment

> “Real-world use of tebentafusp as a backbone with layered liver-directed therapy likely produces outcomes exceeding registrational data.”
> “The comparator bar was viewed as low, deep responses are uncommon, and the OS curves converge over time.”

Source: [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
